M. James Barrett, 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 2,537,016 shares at $1.90 ($4.8M) on 2018-03-22, disclosed to the SEC on 2018-03-23.
Open-market purchase of $4.8M ADAP by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.81 | 104,844 | $190K | 3.9% |
| 2 | $1.81 | 104,844 | $190K | 3.9% |
| 3 | $1.90 | 869,574 | $1.7M | 34.2% |
| 4 | $1.90 | 869,574 | $1.7M | 34.2% |
| 5 | $1.95 | 294,090 | $573K | 11.9% |
| 6 | $1.95 | 294,090 |
| $573K |
| 11.9% |
| Total | $1.90 avg | 2,537,016 | $4.8M | 100% |
| Filing → |
| GLYC | SELL | 2018-05-11 | $340K | — | Filing → |
| SURF | BUY | 2018-04-23 | $2.0M | — | Filing → |
| ADAP | BUY | 2018-03-28 | $13.7M | — | Filing → |